163 results about "Secretory cell" patented technology

The present invention a provides methods for production of heterologous polypeptides, for example amylin, using recombinantly engineered cell lines. Also described are methods engineering cells for high level expression, methods of large scale heterologous protein production, methods for treatment of disease in vivo using viral delivery systems and recombinant cell lines, and methods for isolating novel amylin receptors.

The present invention a provides methods for production of heterologous polypeptides using a variety recombinantly engineered secretory cell lines. The common feature of these cell lines is the absence of expression of at least one endogenous polypeptide. The host cell machinery normally used to produce the endogenous polypeptide is then usurped for the purpose of making the heterologous polypeptide. Also described are methods engineering cells for high level expression, methods of large scale protein production, and methods for treatment of disease in vivo using viral delivery systems and recombinant cell lines.

The invention relates to the field of biology, and discloses a serum-free culture medium which essentially comprises an IMDM (Iscove Modified Dulbecco Medium), L-glutamine, sodium bicarbonate, Hepes, recombinant human insulin, recombinant human transferrin, recombinant human albumin, 2-mercaptoethanol, protocatechuic acid, lipid, amino acid, vitamins, trace elements, Pluronic F-68, hydrocortisone, vitamin C, bonding amine or recombinant human fibronectin, progesterone, putrescine, heparin, serotonin, epidermal growth factors (EGFs), b-fibroblast growth factors (FGF), platelet derive growth factor (PDGF)-BB and insulin-like growth factor (IGF)-I. The serum-free culture medium is clear in chemical components, free from animal sources and serum and safe and ideal in cell cultivation and avoids the doped animal components and unstable batches, and the results of the cultured mesenchymal stem cells show that the total cellular score, the cell phenotype and the secretory cell factors are normal, so that the serum-free culture medium has good industrial application prospect.

Biological agents such as secretory cells are encapsulated in a hydrophilic gel made of agarose or collagen-agarose and gelatin sponge-agarose combinations. In a preferred embodiment, semi-solid beads are formed from a suspension containing collagen, agarose and secretory cells such as pancreatic islets, the collagen is polymerized to form solid, agarose-collagen beads and the solid beads are coated with agarose. Coating is preferably by rolling the solid beads in about 5-10% agarose, contacting the rolled beads with mineral oil and washing oil from the beads. Beads containing secretory cells can be transplanted into a mammal to treat a condition caused by impaired secretory cell function.

The invention relates to the technical field of adipose mesenchymal stem cells in the technical field of cell therapy, in particular to a method for enhancing an immune regulating function and a migration capacity of adipose mesenchymal stem cells. Primary culture and secondary culture are performed to the adipose mesenchymal stem cells obtained through separation, and then short-time culture is performed by using culture medium containing low-concentration TLR3 activator Poly(I:C). After Poly(I:C) co-stimulation culture is performed, the obtained adipose mesenchymal stem cells with a brand new phenotype have a stronger migration capacity, the levels of secreting cytokine and chemotactic factor are changed and a stronger immunosuppressive function is reflected on the whole.

The invention relates to the discovery that the proliferation and survival of pancreatic progenitor cells can be enhanced by contacting the cells with, (1) a caspase inhibitor sufficient to reduce apoptosis in the pancreatic endocrine cells; and, (2) a growth factor in an amount sufficient to increase the level of activated Akt in the pancreatic endocrine cells.

Methods, uses, agents and compositions useful for the diagnosis, prevention and/or treatment of inflammatory conditions, such as neuroinflammatory conditions such as multiple sclerosis, and for the identification and selection of inflammatory cytokine-secreting T cell or a precursor thereof, based on the expression and/or modulation of melanoma cell adhesion molecule (MCAM) are disclosed.

The invention discloses an anti-EGFRvIII chimeric antigen receptor, an encoding gene, a recombinant expression vector, a construction method of the recombinant expression vector, and an application. The anti-EGFRvIII chimeric antigen receptor comprises CD8 leader chimeric receptor signal peptide, an EGFRvIII single-chain antibody light chain VL, Optimal Linker C, an EGFRvIII single-chain antibody heavy chain VH, a CD8 Hinge chimeric receptor hinge, a CD8 Transmembrane chimeric receptor transmembrane domain, a CD137 chimeric receptor co-stimulated factor and a TCR chimeric receptor T cell activating domain which are connected in series. Moreover, the invention discloses an encoding gene of the anti-EGFRvIII chimeric antigen receptor, a recombinant expression vector, a construction method of the recombinant expression vector, and an application. Secretion of cell factors and an in-vitro killing effect of CAR-T cells are obviously improved, and the CAR-T cells have an outstanding clinical treatment effect.

The invention discloses a preparing method for clinic level cells for enhancing the immune modulating function of MSCs. The preparing method is suitable for culturing the mesenchymal stem cells from bone marrow, fat and the umbilical cord. A serum-free complete medium is adopted to culture the mesenchymal stem cells from umbilical cord tissue, a traditional method is improved by applying a secondary inoculation method, and the obtaining rate of primary cells is increased. Imidazoquinoline R848 with the concentration of 1-5 micrograms/milliliters and recombinant human interferon I FN-alpha-2b with the concentration of 100-200 units/milliliters are applied as pretreatment factors and obviously induce high expression of the MSCs and secretory cell factors VEGF, HGF and PGE-2, the capacity for modulating immune and promoting tissue regeneration of the MSCs is brought into play better, the multiplication capacity and the capacity for resisting NK cell killing of the MSCs can be improved obviously, and the pretreated MSCs have the enhanced capacity for suppressing lymphocyte proliferation and can be applied to treatment on the GVHD with T cells as the principal and other autoimmune diseases better.

The invention discloses an anti-human PD-L1 antibody with high affinity, high specificity and multiple antigen recognition epitopes and having higher functionality. The PD-L1 monoclonal antibody can be specifically combined with PD-1, and can effectively block combination of PD-L1 and PD-1 protein, specifically relieve immune negative regulation of PD-L1, and activate T cell secretory cell factors. All the functions can reach a currently unique level of PD-L1 targeted drug Tecentriq (MPDL3280A), and partial antibodies have greater diversity by being different from epitope of Tecentriq. One PD-L1 antibody can promote combination of PD-L1 with PD-1 protein, but can still relieve immune negative regulation of PD-L1, and activate T cell secretory cell factors.

The invention relates to a monoclonal antibody capable of recognizing a human leukocyte differentiation antigen CK8, a secretory cell strain, a preparation method thereof and application in immunodetection. According to the technical scheme, 340-365 amino acid sequences at the C tail end of CK8 protein are selected as antigen peptides, and the antigen peptides are coupled with KLH carrier protein to obtain the immunogen; the amino acid sequence of the antigen peptide is shown as SEQID1, a mouse is immunized, and the mouse hybridoma cell strain 14C2 capable of efficiently secreting the anti-CK8 protein monoclonal antibody and the anti-CK8 protein monoclonal antibody secreted by the cell strain are obtained through cell fusion, screening and subcloning. The antibody obtained by the scheme has high specificity and sensitivity, can specifically recognize cells expressing the CK8 protein, and is suitable for immunological detection, especially immunohistochemical detection.

The invention discloses an anti-CD138 chimeric antigen receptor, a coding gene, a recombinant expression vector and a construction method and an application of the recombinant expression vector. The anti-CD138 chimeric antigen receptor comprises a CD8leader chimeric receptor signal peptide, a light chain VH of the CD138 single-chain antibody, an Optimal Linker C, a heavy chain VL of a CD138 single-chain antibody, a CD8Hinge chimeric receptor hinge, a CD8Transmembrane chimeric receptor transmembrane domain, a CD137 chimeric receptor co-stimulation factor and a TCR chimeric receptor T-cell activation domain, which are serially connected in sequence. In addition, the invention discloses the coding gene of the anti-CD138 chimeric antigen receptor, the recombinant expression vector and the construction method and the application of the recombinant expression vector. According to the anti-CD138 chimeric antigen receptor, the secretion of cell factors and the in vitro killing effect of CAR-T (Chimeric Antigen Receptor T-Cell Immunotherapy) cells can be remarkably improved, and the clinical treatment effect is outstanding.

The invention provides an application of a method for the autocrine secretion of an extracellular matrix by stem cells and the induction of the stem cells to become hepatocytes. The extracellular matrix is secreted by inducing bone marrow mesenchymal stem cells and removes the matrix of the bone marrow mesenchymal stem cells. The invention concretely provides the method for inducing the bone marrow mesenchymal stem cells into hepatocytes by the extracellular matrix according to actual demands. The method for generating the hepatocytes through induction has the advantages of high efficiency, practicality, high induction efficiency and good differentiation effect, and the glycogen synthesis capability and the urea synthesis capability of the hepatocytes obtained after the induction are strong.